Insight into Discovery of Next Generation Reversible TMLR Inhibitors...
Background: Epidermal growth factor receptor (EGFR) is a well-recognised drug target exploited for treating non-small cell lung cancer (NSCLC). Gefitinib and erlotinib are first generation clinically...
View ArticleInfluence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review
Background: Aldo-keto reductase 1C3 (AKR1C3) is an important oxidoreductase with multiple substrates, that are involved in producing extra-testicular androgens. Its activity is influenced by...
View ArticleSmall-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets...
Background: Involvement of mutations in epigenetic mechanism in the development of heterogeneous MDS and its evolution to AML has been understood with at least one mutation and median of 2-3 mutations...
View ArticleThe β 2-Adrenergic Agonist Salbutamol Inhibits Migration, Invasion and...
Background: Breast cancer is the most diagnosed and the major cause of cancer death in women worldwide. Metastasis is the main cause of these deaths. The metastatic cascade involves multiple steps and...
View ArticleMethod to Assess Interactivity of Drugs with Nonparallel Concentration Effect...
Background: Commonly used methods for analyzing interactivity between drugs (e.g. synergy, antagonism) such as isobologram, combination index, and curve shift are based on the Loewe Additivity...
View ArticleIn-silico & In-vitro Identification of Structure-Activity Relationship...
Background: Natural products showed anticancer activity and often induce apoptosis or autophagy in cancer cells through the PI3K/Akt/mTOR signaling pathways. The potential of natural products as PI3Ks...
View ArticlePotential Therapeutic Targets in Energy Metabolism Pathways of Breast Cancer
Background: Mutations in proto-oncogenes and tumor suppressor genes make cancer cells proliferate indefinitely. As they possess almost all mechanisms for cell proliferation and survival like healthy...
View ArticleEpithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in...
Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide and its incidence is steadily rising. Currently, sorafenib remains the only approved standard treatment for patients with...
View ArticleImpact of IL-12 in Cancer
Background: Interleukin 12 (IL-12) is a pleiotropic cytokine that plays an essential role in Th1-type immune response against cancer, a condition where cells in a particular part of the body grow and...
View ArticleImmunomodulatory Drugs (IMiDs) in Multiple Myeloma
Background: Multiple myeloma (MM) is a hematological cancer caused by a proliferation of clonal plasma cells, leading to anemia, renal failure, hypercalcemia and destructive bone lesions resulting in...
View ArticleCoinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of...
Background: Patients with Multiple Myeloma suffer from dysregulation of the immune system and new therapeutic options targeting the immune systems such as monoclonal antibodies or specific Cell therapy...
View ArticleImmunomodulatory Activity of MicroRNAs: Potential Implications for Multiple...
Multiple myeloma (MM) is an incurable plasma cell neoplasm accounting for about 10% of all hematologic malignancies. Recently, emerging evidence is disclosing the complexity of bone marrow interactions...
View ArticleMultiple Myeloma and the Immune Microenvironment
One of the great advances in the field of cancer therapy in recent years is the emergence of immune therapies. Immune therapies, especially immune checkpoint inhibitors, have shown promising results in...
View ArticleTargeting the Immune Niche within the Bone Marrow Microenvironment: The Rise...
Background: Multiple Myeloma (MM) cells inhibit the development of an effective anti- MM immune response via defects in T cell function, ineffective antigen presentation; reduced phagocytic capacity;...
View ArticleStem Cell Transplantation in Multiple Myeloma
High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) remains the standard of care for patients younger than 65 years of age with multiple myeloma (MM). However, this...
View Article